Varicella
Conditions
Keywords
vaccine efficacy, varicella vaccine, safety, immunogenicity
Brief summary
The goal of this clinical trial is to evaluate the efficacy, safety and immunogenicity of a live attenuated varicella vaccine manufactured by Beijing Institute of Biological Products Co., Ltd in healthy children.
Detailed description
This trial is aim to evaluate the efficacy, safety and immunogenicity of a live attenuated varicella vaccine manufactured by Beijing Institute of Biological Products Co., Ltd in healthy children aged 1-12 years old. This study will be conducted in two stage. the stage 1 adopts an open design, and 20 subjects aged 18\ 59 and 13\ 17 years old (18\ 59 years old→ 13\ 17 years old, sequentially enrolled) are enrolled, and 1 dose of the trial vaccine is administered to explore safety. The stage 2 adopts a randomized, blinded, placebo-controlled design, 12400 healthy participants aged 1-12 years old will be randomly assigned into experimental group or control group with the ratio 1:1.
Interventions
0.5 ml/vial
BIOLOGICALPlacebo of live attenuated varicella vaccine
0.5 ml/vial
Sponsors
Beijing Institute of Biological Products Co Ltd.
Jiangsu Province Center for Disease Control and Prevention
China National Biotec Group Company Limited
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
1 Years to 59 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy volunteer between 13 - 59 years old for Stage 1, 1-12 years old for Stage 2, and be able to provide legal identification ; * Subject and/or guardian has the ability to understand study requirements and processes, consent to participate in clinical trials, and sign informed consent forms; * Consent to use effective contraception during study participation, no pregnancy and no family planning (for women of childbearing potential or their spouses); * Axillary temperature ≤ 37.0 °C on the day of enrollment;
Exclusion criteria
* Has received any varicella vaccine before ( Not applicable to Stage 1）; * Has history of varicella or herpes zoster infection, or contact with varicella/shingles patients or suspected varicella/shingles patients within 30 days before enrollment ( Not applicable to Stage 1）; * Currently using salicylates (including salicylic acid, aspirin, diflunisalin, p-aminosalicylate (sodium), dicalicylate, benoxate, etc.), or plan to use it for a long time during the study； * Have had febrile illness (axillary temperature ≥ 38.5 °C) or used antipyretic, analgesic, anti-allergic drugs (such as acetaminophen, ibuprofen, aspirin, loratadine, cetirizine, etc.) 3 days before vaccination； * Have a history of allergy to vaccine components and excipients or severe drug allergy, such as anaphylactic shock, allergic laryngeal edema, Henoch-Schönlein purpura, thrombocytopenic purpura, local allergic necrosis (Arthus) reaction, severe urticaria, etc； * Have a history of epilepsy, convulsions or convulsions, and have a family history of severe neurological disease or psychosis * Immunocompromised or diagnosed with congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia, systemic lupus erythematosus, rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, or other autoimmune diseases； * With severe congenital malformations, hereditary diseases, serious cardiovascular diseases, serious liver/kidney diseases, complicated diabetes, malignant tumors, and severe malnutrition * Immunosuppressant therapy, such as long-term oral or injectable glucocorticoid therapy (≥ 14 days, dose ≥2 mg/kg/day or ≥20 mg/day or equivalent to prednisone), within 3 months prior to enrollment or planned within 30 days of vaccination, but topical medications (e.g., ointments, eye drops, inhalers, or nasal sprays) are not restricted * Have received blood/blood-related products or immunoglobulins 3 months prior to vaccination, or plan to use such products 30 days after vaccination； * Have received a live attenuated vaccine within 30 days prior to the trial vaccine, or any vaccine within 14 days prior to vaccination; * Asplenectomy or splenectomy due to any condition (e.g. splenectomy); * Those with a history of thrombocytopenia or other coagulation disorders, which may cause contraindications to subcutaneous injection; * Suffering from various infectious, purulent or allergic skin diseases; * Are participating in other investigational or unregistered clinical trials of products (drugs, vaccines or devices, etc.), or have plans to participate in other clinical trials before the end of this clinical trial; * Has any other factors that are not suitable for participation in the clinical trial in the judgment of the investigator
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The incidences of varicella in each group | number of cases reported 30 days after vaccination | The first 24 cases of varicella occurred 30 days after injection will be collected |
| The efficacy of the live attenuated varicella vaccine | number of cases reported 30 days after vaccination | The vaccine efficacy will be calculated based on the reported cases occurred 30 days after vaccination |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The incidences of adverse events (AEs) | within 30 days after vaccination | AEs occurred within 30 days after injection will be collected |
| The incidences of serious adverse events (SAEs) | at least 6 months after vaccination | SAEs occurred within 6 months after vaccination will be collected |
| The geometric mean titer (GMT) in the immunogenicity subgroup | 30 days after vaccination | Geometric mean titer (GMT) will be measured before and 30 days after vaccination |
| The vaccine efficacy against laboratory-confirmed cases of moderate and severe varicella | number of cases reported 30 days after vaccination | The vaccine efficacy will be calculated based on the reported cases occurred 30 days after vaccination |
| The geometric mean fold increase (GMI) of the immunogenicity subgroup | 30 days after vaccination | Geometric mean fold increase (GMI) of the immunogenicity group will be calculated based on the geometric mean titer |
| The immune persistence of the immunogenicity subgroup | 1 year, 2 years, and 3 years after vaccination | Geometric mean titer (GMT) will be measured |
| The seroconversion rate of the immunogenicity subgroup | 30 days after vaccination | The seroconversion rate will be calculated before and 30 days after vaccination |
| The vaccine efficacy against clinical-confirmed cases | number of cases reported 30 days after vaccination | calculated based on the reported cases occurred 30 days after vaccination |
Countries
China
Outcome results
None listed